Comparative Pharmacology
Head-to-head clinical analysis: LEVONEST versus TRI ESTARYLLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONEST versus TRI ESTARYLLA.
LEVONEST vs TRI-ESTARYLLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.
Combination hormonal contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Drospirenone is a spironolactone analogue with anti-mineralocorticoid and antiandrogenic activity, also suppressing ovulation and increasing cervical mucus viscosity.
One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.
One tablet (ethinyl estradiol 0.03 mg / norgestimate 0.18-0.215-0.25 mg) orally once daily for 21 days followed by 7 placebo days.
None Documented
None Documented
The terminal elimination half-life is approximately 24-30 hours. This relatively long half-life supports once-daily dosing and allows for stable plasma concentrations within 5-7 days of continuous use.
Terminal elimination half-life is 4-6 hours; clinical context: allows twice-daily dosing for stable blood levels.
Renal excretion of conjugated metabolites accounts for approximately 60-80% of an administered dose; fecal elimination via bile accounts for 20-40%.
Renal: approximately 60% as unchanged drug and metabolites; Biliary/fecal: approximately 40%, primarily as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive